IFNB1 Antikörper (Center)

Produktnummer ABIN302819

Produktdetails anti-IFNB1 Antikörper

Target: IFNB1 (Interferon, beta 1, Fibroblast (IFNB1))

Bindungsspezifität: Center

Reaktivität: Human, Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser IFNB1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Spezifität: This antibody reacts to an 17 amino acid peptide from near the center of IFN-b.

Aufreinigung: Immunoaffinity Chromatography

Immunogen: Synthetic peptide corresponding to an 17 amino acid peptide from near the center of human IFN-b.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Western Blot: 5 μg/mL. Immunohistochemistry on Paraffin Sections: 5 μg/mL.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1.0 mg/mL

Buffer: PBS containing 0.02 % Sodium Azide as preservative.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: DO NOT FREEZE!!

Lagerung: 4 °C

Informationen zur Lagerung: Store the antibody undiluted at 2-8 °C.

Details zu IFNB1

Target: IFNB1 (Interferon, beta 1, Fibroblast (IFNB1))

Andere Bezeichnung: IFNB / Interferon beta (IFNB1 Produkte)

Hintergrund: The mammalian type I Inteferons (IFN1) are produced in response to viral infection and other inducers. They are divided into alpha and beta subtypes leukocytes and fibroblasts reactivity. The human IFN alphas are encoded by a family of at least 15 different genes, while IFN beta is the unique member of its subtype. There is approximately 50 % amino acid homology between the alpha and beta subtypes. Both IFN subtypes are pleiotropic cytokines and have a similar range of biological activities. Differences between alpha subtypes, and between IFN alpha and betas, are in potency and cell type specific activities. In particular, IFN beta elicits a markedly higher antiproliferation response in some cell types such as, embryonal carcinoma, melanoma and melanocytes than do IFN alphas. Higher potency of IFN beta in treatment of multiple sclerosis and certain cancers has been observed. Type I IFNs signal through binding to a common cell surface receptor. Two chains of the receptor, IFNAR1 and IFNAR2, have been identified. Both chains are necessary for function and in the absence of either there is neither high affinity binding nor biological activity. The intracellular portions of the receptor subunits are bound by tyrosine kinases, Jak1 and Tyk2, members of the Janus kinase family. Upon ligand binding these kinases are activated and phosphorylate members of the STAT family of transcription factors, as well as IFNAR1 and 2.Synonyms: Fibroblast interferon, IFB, IFN-beta, IFNB1

Gen-ID: 15977

NCBI Accession: NP_034640

UniProt: P01575

Pathways: JAK-STAT Signalweg, T-Zell Rezeptor Signalweg, TLR Signalweg, Regulation of Leukocyte Mediated Immunity, Production of Molecular Mediator of Immune Response, Positive Regulation of Endopeptidase Activity, Hepatitis C, Autophagie, Inflammasome